First launch for edoxaban as eribulin also reaches the Japanese market
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has launched the oral direct Factor Xa inhibitor Lixiana (edoxaban) in Japan, its first market worldwide, for the prevention of venous thromboembolism following major orthopaedic surgery.